Howard McLeod

Cited by

	All	Since 2019
Citations	57144	15866
h-index	122	57
i10-index	505	287

3000

1500

750

2250

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024199 308 429 731 909 1485 1683 2229 2250 2459 2362 2571 2709 2905 2886 2969 2876 2728 2721 2700 2800 2823 2952 2679 2388 2206

Public access

View all

196 articles

29 articles

available

not available

Based on funding mandates

Co-authors

Teri E. KleinStanford UniversityVerified email at stanford.edu
Mark RatainLeon O. Jacobson Professor of Medicine, The University of ChicagoVerified email at uchicago.edu
Alison Motsinger-ReifNational Institute of Environmental Health SciencesVerified email at nih.gov
Richard Goldberg MDProfessor emeritus, West Virginia UniversityVerified email at hsc.wvu.edu
Mary V. RellingSt. Jude Children's Research HospitalVerified email at stjude.org
Daniel L HertzUniversity of MichiganVerified email at med.umich.edu
William E EvansSt. Jude Children's Research HospitalVerified email at stjude.org
Brian F. GageProfessor of Medicine, Washington University in St. LouisVerified email at im.wustl.edu
LISA A. CAREY MD, ScM, FASCOUniversity of North Carolina Lineberger Comprehensive Cancer CenterVerified email at med.unc.edu
Russ B AltmanProfessor Stanford UniversityVerified email at stanford.edu
Deepak VooraDepartment of Veterans Affairs; Duke University Medical CenterVerified email at duke.edu
Jai N. Patel, PharmD, BCOP, CPPChair, Cancer Pharmacology & Pharmacogenomics, Levine Cancer Institute, Atrium HealthVerified email at atriumhealth.org
Todd C. KnepperAssociate Member, Precision Medicine, Moffitt Cancer CenterVerified email at moffitt.org
Jaap VerweijErasmus University Medical Center and Cancer Drug Development ForumVerified email at cddf.org
David Ofori-AdjeiProfessor of Medicine & Therapeutics, University of GhanaVerified email at noguchi.ug.edu.gh
David E. LanfearHenry Ford HospitalVerified email at hfhs.org
E Claire DeesUNCVerified email at med.unc.edu
John SpertusSaint Luke's Mid America Heart Institute/University of Missouri - Kansas CityVerified email at umkc.edu
Derek Van BoovenDirector Research Data, John P Hussman Insitute for Human Genomics, University of MiamiVerified email at med.miami.edu
Frank J. GonzalezNational Cancer InstituteVerified email at mail.nih.gov

Howard McLeod

Utah Tech University

Verified email at utahtech.edu - Homepage

personalized medicine cancer genomics Pharmacogenomics


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
Pharmacogenomics—drug disposition, drug targets, and side effects WE Evans, HL McLeod New England journal of medicine 348 (6), 538-549, 2003	2525	2003
Doxorubicin pathways: pharmacodynamics and adverse effects CF Thorn, C Oshiro, S Marsh, T Hernandez-Boussard, H McLeod, ... Pharmacogenetics and genomics 21 (7), 440-446, 2011	2059	2011
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose MJ Rieder, AP Reiner, BF Gage, DA Nickerson, CS Eby, HL McLeod, ... New England Journal of Medicine 352 (22), 2285-2293, 2005	1846	2005
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ... Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008	1002	2008
Genomics and drug response L Wang, HL McLeod, RM Weinshilboum New England Journal of Medicine 364 (12), 1144-1153, 2011	771	2011
Platinum neurotoxicity pharmacogenetics SR McWhinney, RM Goldberg, HL McLeod Molecular cancer therapeutics 8 (1), 10-16, 2009	717	2009
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs S Zhou, SY Chan, BC Goh, E Chan, W Duan, M Huang, HL McLeod Clinical pharmacokinetics 44, 279-304, 2005	612	2005
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity MM Ameyaw, F Regateiro, T Li, X Liu, M Tariq, A Mobarek, N Thornton, ... Pharmacogenetics and Genomics 11 (3), 217-221, 2001	609	2001
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update U Amstutz, LM Henricks, SM Offer, J Barbarino, JHM Schellens, JJ Swen, ... Clinical Pharmacology & Therapeutics 103 (2), 210-216, 2018	606	2018
UGT1A1* 28 genotype and irinotecan-induced neutropenia: dose matters JM Hoskins, RM Goldberg, P Qu, JG Ibrahim, HL McLeod Journal of the National Cancer Institute 99 (17), 1290-1295, 2007	580	2007
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer Y Wang, T Jatkoe, Y Zhang, MG Mutch, D Talantov, J Jiang, HL McLeod, ... Journal of clinical oncology 22 (9), 1564-1571, 2004	576	2004
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia HL McLeod, EY Krynetski, MV Relling, WE Evans Leukemia 14 (4), 567-572, 2000	571	2000
PI3K/Akt/mTOR pathway as a target for cancer therapy D Morgensztern, HL McLeod Anti-cancer drugs 16 (8), 797-803, 2005	569	2005
Carbamazepine, HLA-B1502* and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA Recommendations PB Ferrell, HL McLeod Pharmacogenomics 9 (10), 1543-1546, 2008	506	2008
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism GJ Peters, HHJ Backus, S Freemantle, B Van Triest, G Codacci-Pisanelli, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002	501	2002
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine AJ Black, HL McLeod, HA Capell, RH Powrie, LK Matowe, SC Pritchard, ... Annals of internal medicine 129 (9), 716-718, 1998	491	1998
Strategies for enzyme/prodrug cancer therapy G Xu, HL McLeod Clinical Cancer Research 7 (11), 3314-3324, 2001	484	2001
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. X Wei, HL McLeod, J McMurrough, FJ Gonzalez, P Fernandez-Salguero The Journal of clinical investigation 98 (3), 610-615, 1996	476	1996
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update LB Ramsey, SG Johnson, KE Caudle, CE Haidar, D Voora, RA Wilke, ... Clinical Pharmacology & Therapeutics 96 (4), 423-428, 2014	471	2014
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study JG Scott, A Berglund, MJ Schell, I Mihaylov, WJ Fulp, B Yue, E Welsh, ... The lancet oncology 18 (2), 202-211, 2017	468	2017

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Follow

Cited by

Co-authors